Epithelial ovarian cancer is one of the most fatal gynaecological malignancies in adult women with an estimated 1,580 new cases diagnosed and 1,047 deaths estimated in Australia during 2017. N-glycomic studies have extensively reported aberrant patterns in the ovarian cancer tumour microenvironment. Therefore, obtaining spatial information is essential to uncover tumour-specific N-glycan alterations in ovarian cancer development and progression. Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) was employed to investigate the spatial distribution of N-glycans on formalin-fixed paraffin-embedded (FFPE) ovarian cancer tissue sections from both early-stage (n = 3) and late-stage (n = 3) patients. Tumour-specific N-glycans were identified and structurally characterised by PGC-LC-ESI-MS/MS, and then assigned to high-resolution images obtained from MALDI-MSI. A total of 14 N-glycans were visualised as ion intensity maps while 42 N-glycans (including structural and compositional isomers) were identified and structurally characterised. The spatial distribution of high mannose, complex neutral, bisecting and sialylated N-glycan families were only observed to be localised to the tumour regions of late-stage ovarian cancer patients relative to early-stage patients. Potential N-glycans diagnostic markers that emerged include the high mannose structure, (Hex)6 + (Man)3(GlcNAc)2, the bisecting structure, (Hex)1 (HexNAc)3 (Deoxyhexose)1 + (Man)3(GlcNAc)2, and the sialylated structure, (Hex)2 (HexNAc)2 (NeuAc)1 + (Man)3(GlcNAc)2. These observations require validation on large patient cohorts, by utilising tissue microarrays (TMAs) as well as evaluation of specific glyco-gene expression levels.